If your employer-sponsored insurance copay for a generic is over $15, then 80% of the time, you are overpaying. In @annalsofim.bsky.social , we analyzed nationwide data on employer plans vs @mcuban.bsky.social @costplusdrugs.com Here is a breakdown on who stands to save most. 🧵

According to MedPAC, details of the Part D redesign mean that some enrollees will hit their $2,000 OOP maximum much faster than I realized. In one example, they show how one could hit the max with just $470 in spending.

If you are downloading data right now - I recommend asdfree.com. Anthony Damico has R scripts to download ~50 public surveys, create the survey design and save them locally. If you are an R user this will things go much faster!

HHS announces the next 15 drugs to negotiate under Part D! Great to see this progress. Quite a few cancer treatments, which will mean more savings potential than in the first year's drug list (cancer drugs get limited or no rebates today). Good news for taxpayers and Medicare spending!

📰 15 more drugs up for Medicare price negotiation this year. Including the blockbuster diabetes/obesity drug semaglutide!! 💊🩺📈🧪 www.cms.gov/newsroom/pre...

It was a pleasure to write this piece for Health Affairs on risk adjustment in Medicare. Risk adjustment modifies payments to health plans or ACOs based on patient/beneficiary characteristics. Here's a very brief summary of my thoughts🧵 www.healthaffairs.org/doi/abs/10.1...

Starting today, Medicare beneficiaries will have their annual out-of-pocket drug costs capped at $2,000 as a result of the Inflation Reduction Act. www.kff.org/medicare/iss...

Here are the first five sets of slides: 01 Introduction: psantanna.com/DiD/01_Intro... 02 Classical 2x2 setup: psantanna.com/DiD/02_two_b... 03 Clustering issues: psantanna.com/DiD/03_Clust... 04 Functional form: psantanna.com/DiD/04_Funct... 05 Covariates: psantanna.com/DiD/05_Covar...